4/A: Janux Therapeutics Director Dobmeier Amends Filing to Correct RSU and Stock Option Numbers

Eric Dobmeier, a director at Janux Therapeutics, filed an amended Form 4 to correct the number of Restricted Stock Units (RSUs) and stock options granted on July 19, 2024.

Summary

• Eric Dobmeier, a director of Janux Therapeutics, Inc. [JANX], filed an amendment to a previous Form 4 filing.
• The amendment corrects the number of Restricted Stock Units (RSUs) and stock options granted to Dobmeier on July 19, 2024.
• The corrected filing shows Dobmeier was granted 1,231 RSUs, vesting fully on July 19, 2025, contingent upon continued service.
• Dobmeier was also granted an option to purchase 4,111 shares of common stock at an exercise price of $44.68, vesting in twelve equal monthly installments over one year, also subject to continuous service.
• Following the reported transactions, Dobmeier directly owns 6,231 shares of common stock and has options for 4,111 shares.
• The original filing date was July 22, 2024, and the amendment was filed on July 24, 2024.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting previously reported information. It doesn't contain any significantly positive or negative news, but the grants themselves are a positive sign of aligning director interests with shareholders.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders.
• The vesting schedules incentivize continued service and contribution to the company.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Stock option and RSU grants are common compensation practices for directors and executives in the biotechnology industry, aligning their interests with shareholders.
• Vesting schedules are typically structured to incentivize long-term commitment and performance, similar to practices at companies like Amgen, Gilead, and Regeneron.

Stakeholder Impact

• The corrected information provides accurate data to shareholders regarding insider ownership.
• The grants of RSUs and stock options can motivate the director to act in the best interests of the company and its shareholders.

Key Dates